Hospital-Associated Infectious Diseases and Antibiotic Therapy

A special issue of Antibiotics (ISSN 2079-6382). This special issue belongs to the section "Antibiotic Therapy in Infectious Diseases".

Deadline for manuscript submissions: 31 December 2025 | Viewed by 2072

Special Issue Editors


E-Mail
Guest Editor
Clinical Microbiology and Virology Unit, “A. Manzoni” Hospital, 23900 Lecco, Italy
Interests: bacteriology; antimicrobial resistance; antimicrobial stewardship; clinical microbiology; bloodstream infection; new diagnostic approaches; infection control
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Clinical Microbiology and Virology Unit, “A. Manzoni” Hospital, 23900 Lecco, Italy
Interests: bacteriology; antimicrobial resistance; antimicrobial stewardship; clinical microbiology; molecular microbiology; infection control

Special Issue Information

Dear Colleagues,

Hospital-associated infectious diseases represent a significant public health issue, leading to prolonged hospital stays with considerable costs for the healthcare system. Their spread is responsible for an increased use of antimicrobial therapy, an important driver in the development of multidrug-resistant (MDR) microorganisms. Appropriate interventions in terms of infection prevention and control measures are required to mitigate the burden of these infections.

This Special Issue seeks to publish research articles and reviews investigating the epidemiology, preventive measures and diagnostic tools associated with hospital-associated infectious diseases, as well as the appropriate use of antimicrobial therapy for their management, with a particular focus on the treatment of MDR pathogens and the activity of new drugs against these pathogens.

Dr. Carola Mauri
Dr. Alessandra Consonni
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • hospital-associated infectious diseases
  • epidemiology
  • treatment
  • antibiotic stewardship
  • antimicrobial resistance
  • multi-drug resistance

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

18 pages, 1942 KB  
Article
Surveillance and Characterization of Vancomycin-Resistant and Vancomycin-Variable Enterococci in a Hospital Setting
by Claudia Rotondo, Valentina Antonelli, Alberto Rossi, Silvia D’Arezzo, Marina Selleri, Michele Properzi, Silvia Turco, Giovanni Chillemi, Valentina Dimartino, Carolina Venditti, Sara Guerci, Paola Gallì, Carla Nisii, Alessia Arcangeli, Emanuela Caraffa, Stefania Cicalini and Carla Fontana
Antibiotics 2025, 14(8), 795; https://doi.org/10.3390/antibiotics14080795 - 4 Aug 2025
Viewed by 972
Abstract
Background/Objectives: Enterococci, particularly Enterococcus faecalis and Enterococcus faecium, are Gram-positive cocci that can cause severe infections in hospitalized patients. The rise of vancomycin-resistant enterococci (VRE) and vancomycin-variable enterococci (VVE) poses significant challenges in healthcare settings due to their resistance to multiple [...] Read more.
Background/Objectives: Enterococci, particularly Enterococcus faecalis and Enterococcus faecium, are Gram-positive cocci that can cause severe infections in hospitalized patients. The rise of vancomycin-resistant enterococci (VRE) and vancomycin-variable enterococci (VVE) poses significant challenges in healthcare settings due to their resistance to multiple antibiotics. Methods: We conducted a point prevalence survey (PPS) to assess the prevalence of VRE and VVE colonization in hospitalized patients. Rectal swabs were collected from 160 patients and analyzed using molecular assays (MAs) and culture. Whole-genome sequencing (WGS) and core-genome multilocus sequence typing (cgMLST) were performed to identify the genetic diversity. Results: Of the 160 rectal swabs collected, 54 (33.7%) tested positive for the vanA and/or vanB genes. Culture-based methods identified 47 positive samples (29.3%); of these, 44 isolates were identified as E. faecium and 3 as E. faecalis. Based on the resistance profiles, 35 isolates (74.5%) were classified as VRE, while 12 (25.5%) were classified as VVE. WGS and cgMLST analyses identified seven clusters of E. faecium, with sequence type (ST) 80 being the most prevalent. Various resistance genes and virulence factors were identified, and this study also highlighted intra- and inter-ward transmission of VRE strains. Conclusions: Our findings underscore the potential for virulence and resistance of both the VRE and VVE strains, and they highlight the importance of effective infection control measures to prevent their spread. VVE in particular should be carefully monitored as they often escape detection. Integrating molecular data with clinical information will hopefully enhance our ability to predict and prevent future VRE infections. Full article
(This article belongs to the Special Issue Hospital-Associated Infectious Diseases and Antibiotic Therapy)
Show Figures

Figure 1

Review

Jump to: Research

14 pages, 1846 KB  
Review
New Antibiotics for Treating Infections Caused by Multidrug-Resistant Bacteria
by Elisabete Machado and João Carlos Sousa
Antibiotics 2025, 14(10), 997; https://doi.org/10.3390/antibiotics14100997 - 5 Oct 2025
Viewed by 786
Abstract
Infections caused by antibiotic resistant bacteria pose a serious threat to global health, leading to higher medical costs, longer hospital stays, and increased morbidity and mortality. An increasing number of bacteria have been implicated in untreatable infections due to multiple resistance mechanisms. In [...] Read more.
Infections caused by antibiotic resistant bacteria pose a serious threat to global health, leading to higher medical costs, longer hospital stays, and increased morbidity and mortality. An increasing number of bacteria have been implicated in untreatable infections due to multiple resistance mechanisms. In 2017, the World Health Organization published a list of the most important antibiotic resistant bacteria worldwide, for which there is an urgent need to develop new therapeutic options. In recent years, fortunately, new antibiotics have been approved for the treatment of infections caused by multidrug-resistant bacteria. The purpose of this review is to present the most impactful new antibiotics that are currently available for the treatment of these infections. The discovery of new therapeutic strategies will help to limit the spread of multidrug-resistant bacteria, but careful prescribing, appropriate use and monitoring of resistant strains will be crucial to ensure that they remain effective in the future. Full article
(This article belongs to the Special Issue Hospital-Associated Infectious Diseases and Antibiotic Therapy)
Show Figures

Figure 1

Back to TopTop